Cirtuvivint

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Cirtuvivint (SM08502) 是一种有效的具有口服活性的 CDC 样激酶 (CLK) 抑制剂，可用于实体瘤的研究。

Cirtuvivint (SM08502) is a potent and orally active CDC-like kinase (CLK) inhibitor. Cirtuvivint can be used for solid tumors research.

Cirtuvivint (SM08502) inhibits serine and arginine rich splicing factor (SRSF) phosphorylation and disrupted spliceosome activity, which is associated with inhibition of Wnt pathway-related gene and protein expression. Cirtuvivint induces the generation of splicing variants of Wnt pathway genes, suggesting that its mechanism for inhibition of gene expression includes effects on alternative splicing.

Orally administered Cirtuvivint (SM08502) significantly inhibits growth of gastrointestinal tumors and decreased SRSF phosphorylation and Wnt pathway gene expression in xenograft mouse models.

——

Cell Cycle/DNA Damage

CDK

CDK

——

——

2143917-62-6

427.5

C24H25N7O

>98% (HPLC)

In Vitro:?DMSO 中的溶解度 : 12.5 mg/mL (29.24 mM; 超声助溶 (<60°C)

CN1CCN(CC1)c1cc(ccn1)C(=O)Nc1cc2cc(ccc2cn1)-c1cnn(C)c1

——

(-20℃)

With Ice Pack

≥ 2 years